$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-K Financial Statement

#000071913518000015 Filed on March 13, 2018

Income Statement

Concept	2016 Q4	2016 Q3	2016 Q2
Revenue	$9.494M	$10.06M	$9.295M
YoY Change	14.45%	28.63%	27.78%
Cost Of Revenue	$4.660M	$5.002M	$4.595M
YoY Change	-2.51%	8.98%	11.26%
Gross Profit	$4.830M	$5.062M	$4.700M
YoY Change	37.45%	56.77%	49.68%
Gross Profit Margin	50.87%	50.3%	50.56%
Selling, General & Admin	$5.200M	$2.141M	$2.022M
YoY Change	22.64%	-52.0%	-51.63%
% of Gross Profit	107.66%	42.3%	43.02%
Research & Development	$680.0K	$681.0K	$592.0K
YoY Change	7.94%	17.41%	16.08%
% of Gross Profit	14.08%	13.45%	12.6%
Depreciation & Amortization	$170.0K	$201.0K	$173.0K
YoY Change	-5.56%	-4.29%	-24.78%
% of Gross Profit	3.52%	3.97%	3.68%
Operating Expenses	$5.880M	$5.306M	$5.210M
YoY Change	20.74%	5.07%	11.09%
Operating Profit	-$1.050M	-$245.0K	-$510.0K
YoY Change	-22.57%	-86.55%	-67.1%
Interest Expense	$590.0K	-$720.0K	-$10.00K
YoY Change	-1575.0%	-413.04%	-120.0%
% of Operating Profit
Other Income/Expense, Net		-$720.0K	-$9.000K
YoY Change
Pretax Income	-$460.0K	-$965.0K	-$519.0K
YoY Change	-66.91%	-39.31%	-65.4%
Income Tax	$60.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$520.0K	-$965.0K	-$519.0K
YoY Change	-63.12%	-39.31%	-65.4%
Net Earnings / Revenue	-5.48%	-9.59%	-5.58%
Basic Earnings Per Share	-$0.02	-$0.04	-$0.02
Diluted Earnings Per Share	-$18.21K	-$0.04	-$0.02
COMMON SHARES
Basic Shares Outstanding		27.08M shares	27.05M shares
Diluted Shares Outstanding		27.08M shares	27.05M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.50M	$9.300M	$9.300M
YoY Change	22.88%	-29.55%	-34.04%
Cash & Equivalents	$14.46M	$9.329M	$9.324M
Short-Term Investments
Other Short-Term Assets	$1.200M	$1.400M	$1.300M
YoY Change	-7.69%	-22.22%	-38.1%
Inventory	$6.158M	$5.900M	$6.400M
Prepaid Expenses
Receivables	$4.733M	$3.900M	$3.500M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$26.54M	$20.50M	$20.60M
YoY Change	20.4%	-13.5%	-15.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.449M	$6.500M	$6.500M
YoY Change	-5.3%	-7.14%	-7.14%
Goodwill	$185.0K
YoY Change	0.0%
Intangibles	$1.510M
YoY Change	0.0%
Long-Term Investments
YoY Change
Other Assets	$103.0K	$200.0K	$500.0K
YoY Change	-76.05%	-66.67%	-28.57%
Total Long-Term Assets	$8.571M	$8.600M	$9.000M
YoY Change	-8.88%	-8.51%	-6.25%
TOTAL ASSETS
Total Short-Term Assets	$26.54M	$20.50M	$20.60M
Total Long-Term Assets	$8.571M	$8.600M	$9.000M
Total Assets	$35.11M	$29.10M	$29.60M
YoY Change	11.64%	-12.08%	-13.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.606M	$1.700M	$1.800M
YoY Change	32.29%	-26.09%	5.88%
Accrued Expenses	$2.604M	$2.300M	$2.600M
YoY Change	22.89%	9.52%	36.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$239.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$5.272M	$4.200M	$4.600M
YoY Change	27.93%	-10.64%	17.95%
LONG-TERM LIABILITIES
Long-Term Debt	$2.694M	$2.900M	$3.000M
YoY Change	-8.18%	-3.33%	-3.23%
Other Long-Term Liabilities	$200.0K	$800.0K	$200.0K
YoY Change	-33.33%	166.67%	-66.67%
Total Long-Term Liabilities	$2.694M	$3.700M	$3.200M
YoY Change	-8.18%	12.12%	-13.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.272M	$4.200M	$4.600M
Total Long-Term Liabilities	$2.694M	$3.700M	$3.200M
Total Liabilities	$8.887M	$8.500M	$8.300M
YoY Change	10.48%	0.0%	3.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$23.43M
YoY Change	20.27%
Common Stock	$31.00K
YoY Change	14.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.22M	$20.63M	$21.30M
YoY Change
Total Liabilities & Shareholders Equity	$35.11M	$29.10M	$29.60M
YoY Change	11.64%	-12.08%	-13.2%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2016 Q2
OPERATING ACTIVITIES
Net Income	-$520.0K	-$965.0K	-$519.0K
YoY Change	-63.12%	-39.31%	-65.4%
Depreciation, Depletion And Amortization	$170.0K	$201.0K	$173.0K
YoY Change	-5.56%	-4.29%	-24.78%
Cash From Operating Activities	-$550.0K	$90.00K	-$110.0K
YoY Change	-46.08%	-113.85%	-95.28%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	-$140.0K	-$20.00K
YoY Change	-161.11%	0.0%	-90.48%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$110.0K	-$140.0K	-$20.00K
YoY Change	-65.63%	0.0%	-90.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.770M	60.00K	0.000
YoY Change	-9716.67%	-160.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-550.0K	90.00K	-110.0K
Cash From Investing Activities	-110.0K	-140.0K	-20.00K
Cash From Financing Activities	5.770M	60.00K	0.000
Net Change In Cash	5.110M	10.00K	-130.0K
YoY Change	-465.0%	-101.12%	-90.08%
FREE CASH FLOW
Cash From Operating Activities	-$550.0K	$90.00K	-$110.0K
Capital Expenditures	-$110.0K	-$140.0K	-$20.00K
Free Cash Flow	-$440.0K	$230.0K	-$90.00K
YoY Change	-63.33%	-145.1%	-95.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	bvx	Accretion On Convertible Preferred Stock AccretionOnConvertiblePreferredStock	-222000	USD
CY2016	bvx	Accretion On Convertible Preferred Stock AccretionOnConvertiblePreferredStock	0	USD
CY2017	bvx	Accretion On Convertible Preferred Stock AccretionOnConvertiblePreferredStock	0	USD
CY2017	bvx	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P3Y
CY2015Q4	bvx	Additional Accretion Of Convertible Preferred Stock And Warrants AdditionalAccretionOfConvertiblePreferredStockAndWarrants	221902	USD
CY2015	bvx	Conversion Of Series B Convertible Preferred To Common Stock Amount ConversionOfSeriesBConvertiblePreferredToCommonStockAmount	0	USD
CY2016	bvx	Conversion Of Series B Convertible Preferred To Common Stock Amount ConversionOfSeriesBConvertiblePreferredToCommonStockAmount	0	USD
CY2017	bvx	Conversion Of Series B Convertible Preferred To Common Stock Amount ConversionOfSeriesBConvertiblePreferredToCommonStockAmount	0	USD
CY2015	bvx	Conversion Of Series Preferred Stock And Common Warrants To Series B Preferred Stock Amount ConversionOfSeriesPreferredStockAndCommonWarrantsToSeriesBPreferredStockAmount	13920000	USD
CY2016Q4	bvx	Deferred Tax Liabilities State Taxes Capital DeferredTaxLiabilitiesStateTaxesCapital	19000	USD
CY2017Q4	bvx	Deferred Tax Liabilities State Taxes Capital DeferredTaxLiabilitiesStateTaxesCapital	17000	USD
CY2017	bvx	Defined Contribution Plan Employers Matching Contribution Vesting Percentage After Three Years DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears	1
CY2015	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	-1799000	USD
CY2016	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	-64000	USD
CY2017	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	-183000	USD
CY2015	bvx	Effective Income Tax Rate Reconciliation Warrant Gains EffectiveIncomeTaxRateReconciliationWarrantGains	-0.111
CY2016	bvx	Effective Income Tax Rate Reconciliation Warrant Gains EffectiveIncomeTaxRateReconciliationWarrantGains	0.314
CY2017	bvx	Effective Income Tax Rate Reconciliation Warrant Gains EffectiveIncomeTaxRateReconciliationWarrantGains	0.004
CY2015	bvx	Gain On Conversion Of Warrants And Preferred Shares Net GainOnConversionOfWarrantsAndPreferredSharesNet	13956000	USD
CY2016	bvx	Gain On Conversion Of Warrants And Preferred Shares Net GainOnConversionOfWarrantsAndPreferredSharesNet	0	USD
CY2017	bvx	Gain On Conversion Of Warrants And Preferred Shares Net GainOnConversionOfWarrantsAndPreferredSharesNet	0	USD
CY2015	bvx	Increase Decreasein Accrued Severanceandrelated IncreaseDecreaseinAccruedSeveranceandrelated	0	USD
CY2016	bvx	Increase Decreasein Accrued Severanceandrelated IncreaseDecreaseinAccruedSeveranceandrelated	0	USD
CY2017	bvx	Increase Decreasein Accrued Severanceandrelated IncreaseDecreaseinAccruedSeveranceandrelated	1242000	USD
CY2017	bvx	Numberofproductlines Numberofproductlines	4	product_line
CY2015	bvx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	1427000	USD
CY2016	bvx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	124000	USD
CY2017	bvx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	0	USD
CY2017	bvx	Sales Discount Billing Terms Lower Limit SalesDiscountBillingTermsLowerLimit	P10D
CY2017	bvx	Sales Discount Billing Terms Upper Limit SalesDiscountBillingTermsUpperLimit	P60D
CY2015	bvx	Share Based Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	932771	USD
CY2016	bvx	Share Based Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	1516125	USD
CY2017	bvx	Share Based Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	3144960	USD
CY2016Q4	bvx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Intrinsic Value Closing Stock Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice	3.59
CY2017Q4	bvx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Intrinsic Value Closing Stock Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice	2.60
CY2016Q4	bvx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding With Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWithIntrinsicValue	1211014	shares
CY2017Q4	bvx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding With Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWithIntrinsicValue	2318887	shares
CY2015	bvx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	33520	shares
CY2016	bvx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	9614	shares
CY2017	bvx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	47372	shares
CY2016	bvx	Stock Issued During Period Value Stock Swaps Net StockIssuedDuringPeriodValueStockSwapsNet	12300	USD
CY2015	bvx	Stock Swap To Acquire Options Amount StockSwapToAcquireOptionsAmount	-273000	USD
CY2016	bvx	Stock Swap To Acquire Options Amount StockSwapToAcquireOptionsAmount	-698000	USD
CY2017	bvx	Stock Swap To Acquire Options Amount StockSwapToAcquireOptionsAmount	-557000	USD
CY2015	bvx	Warrant Exercised Amount WarrantExercisedAmount	1519000	USD
CY2016	bvx	Warrant Exercised Amount WarrantExercisedAmount	698000	USD
CY2017	bvx	Warrant Exercised Amount WarrantExercisedAmount	130000	USD
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33021170	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017Q2	dei	Entity Public Float EntityPublicFloat	70900000	USD
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0000719135
CY2017	dei	Entity Registrant Name EntityRegistrantName	BOVIE MEDICAL CORP
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1606000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1583000	USD
CY2016Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	4851000	USD
CY2017Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	5061000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4733000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4857000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2604000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2388000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	419000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	447000	USD
CY2016Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	404000	USD
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	74000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7269000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6711000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49625000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50495000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	575000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	809000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	871000	USD
CY2015	us-gaap	Advertising Expense AdvertisingExpense	500000	USD
CY2016	us-gaap	Advertising Expense AdvertisingExpense	700000	USD
CY2017	us-gaap	Advertising Expense AdvertisingExpense	600000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	568000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	809000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	871000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	118000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	200000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	204000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2016Q4	us-gaap	Assets Assets	35110000	USD
CY2017Q4	us-gaap	Assets Assets	30988000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	26539000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	22547000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5733000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11805000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14456000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9949000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6072000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2651000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4507000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31002832	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33021170	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30859753	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32878091	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	31000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2017	us-gaap	Common Stock Voting Rights CommonStockVotingRights	1
CY2016Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	0	USD
CY2017Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	0	USD
CY2015	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16963000	USD
CY2016	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18712000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19122000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-25000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	25000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-196000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	864000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	555000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	564000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	368000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	14000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10485000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8943000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	534000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	494000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	300000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	187000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	263000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	178000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	519000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	549000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10185000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8756000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	564000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	368000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	386000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	244000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	459000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	294000	USD
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.5
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	109000	USD
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2017Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	92000	USD
CY2015	us-gaap	Depreciation Depreciation	700000	USD
CY2016	us-gaap	Depreciation Depreciation	600000	USD
CY2017	us-gaap	Depreciation Depreciation	600000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	812000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	734000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	696000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	203000	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	20000	USD
CY2015	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	222000	USD
CY2016	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2017	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.34
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.263
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.718
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.289
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.712
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.004
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.012
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.031
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.006
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.015
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.062
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.024
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.037
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3000000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	100000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	100000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	100000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	215000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	179000	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-21000	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-21000	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-5000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	185000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	185000	USD
CY2015	us-gaap	Gross Profit GrossProfit	12557000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	3323000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	4700000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	5062000	USD
CY2016Q4	us-gaap	Gross Profit GrossProfit	4830000	USD
CY2016	us-gaap	Gross Profit GrossProfit	17915000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	4226000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	5042000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	4594000	USD
CY2017Q4	us-gaap	Gross Profit GrossProfit	5899000	USD
CY2017	us-gaap	Gross Profit GrossProfit	19761000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5345000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3886000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5218000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-156000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	196000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-189000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	392000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-23000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1029000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1894000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	303000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	553000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	763000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-532000	USD
CY2015	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	228000	USD
CY2016	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	341000	USD
CY2017	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	53000	USD
CY2015	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	1799000	USD
CY2016	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	64000	USD
CY2017	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	183000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	102000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	379000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-60000	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-60000	USD
CY2016	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	870000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-286000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-103000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	83000	USD
CY2017	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-60000	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	28000	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	16000	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	7000	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3137000	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	249000	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2016Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1510000	USD
CY2017Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1510000	USD
CY2015	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-158000	USD
CY2016	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-158000	USD
CY2017	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-136000	USD
CY2015	us-gaap	Interest Paid InterestPaid	158000	USD
CY2016	us-gaap	Interest Paid InterestPaid	158000	USD
CY2017	us-gaap	Interest Paid InterestPaid	136000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3048000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3276000	USD
CY2016Q4	us-gaap	Inventory Gross InventoryGross	7569000	USD
CY2017Q4	us-gaap	Inventory Gross InventoryGross	8439000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	6158000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	6526000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4521000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5163000	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1411000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1913000	USD
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	157000	USD
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	178000	USD
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	502000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	8887000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	8956000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35110000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30988000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5272000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5973000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	2694000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	239000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	239000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	239000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2455000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2694000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2455000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	140000	USD
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	140000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12779000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5774000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-179000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-921000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-286000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-624000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5786000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2837000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3704000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-5370000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-3950000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-5062000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	8364000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1944000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-519000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-964000	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-523000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3950000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1685000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1308000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1245000	USD
CY2017Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-824000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5062000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	6787000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4014000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5245000	USD
CY2015	us-gaap	Notes Reduction NotesReduction	140000	USD
CY2016	us-gaap	Notes Reduction NotesReduction	0	USD
CY2017	us-gaap	Notes Reduction NotesReduction	0	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2016	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2015	us-gaap	Operating Expenses OperatingExpenses	19543000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	21707000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	25026000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-6986000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-3792000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-5265000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	296000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	74000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	74000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	74000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	74000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	67000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1641000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-94000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	47000	USD
CY2015	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	500000	USD
CY2016	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	USD
CY2017	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	421000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	286000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	624000	USD
CY2015	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	222000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	413000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	496000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11531000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5830000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2013Q4	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	7000000	USD
CY2015	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-239000	USD
CY2016	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-240000	USD
CY2017	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-239000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	209250	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12300	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015	us-gaap	Professional Fees ProfessionalFees	1484000	USD
CY2016	us-gaap	Professional Fees ProfessionalFees	1486000	USD
CY2017	us-gaap	Professional Fees ProfessionalFees	1771000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13718000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13119000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6449000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6408000	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	96000	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	84000	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	179000	USD
CY2017Q4	us-gaap	Purchase Obligation PurchaseObligation	4300000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2160000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2618000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2455000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	779000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	719000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23434000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28496000	USD
CY2015	us-gaap	Salaries And Wages SalariesAndWages	7482000	USD
CY2016	us-gaap	Salaries And Wages SalariesAndWages	9038000	USD
CY2017	us-gaap	Salaries And Wages SalariesAndWages	7906000	USD
CY2015	us-gaap	Sales Discounts Goods SalesDiscountsGoods	300000	USD
CY2016	us-gaap	Sales Discounts Goods SalesDiscountsGoods	600000	USD
CY2017	us-gaap	Sales Discounts Goods SalesDiscountsGoods	500000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	29520000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	7775000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	9295000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	10063000	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	9494000	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	36627000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	8389000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	9799000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	9347000	USD
CY2017Q4	us-gaap	Sales Revenue Net SalesRevenueNet	11348000	USD
CY2017	us-gaap	Sales Revenue Net SalesRevenueNet	38883000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8417000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8565000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11370000	USD
CY2015	us-gaap	Severance Costs1 SeveranceCosts1	0	USD
CY2016	us-gaap	Severance Costs1 SeveranceCosts1	0	USD
CY2017Q4	us-gaap	Severance Costs1 SeveranceCosts1	1524000	USD
CY2017	us-gaap	Severance Costs1 SeveranceCosts1	1524000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	575000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	809000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	871000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P7Y
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.540
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.503
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.680
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.530
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.495
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.621
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2627722	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.46
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	51575	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	119026	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	223340	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	153750	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	443302	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.69
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.95
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	810762	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1728000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.82
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3131447	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3752209	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4860157	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.38
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.00
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	4150334	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1306791	USD
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.62
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.41
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.87
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.09
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1574318	USD
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	768706	USD
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1745506	shares
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2232435	shares
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	443302	shares
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	1.95
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.25
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.40
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	412638	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	612464	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	805748	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	797769	shares
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.01
CY2015	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	100000	USD
CY2016	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	200000	USD
CY2017	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	200000	USD
CY2015	us-gaap	Stock Issued1 StockIssued1	272000	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	698000	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	557000	USD
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	36250	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	176750	shares
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11531000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5830000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	220000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	130000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	427000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	1504000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	23404000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	26223000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	22032000	USD
CY2016Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	0	USD
CY2017Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	1242000	USD
CY2016Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	9169000	USD
CY2017Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	7722000	USD
CY2015	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1799000	USD
CY2016	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	64000	USD
CY2017	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	183000	USD
CY2015	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	200000	USD
CY2016	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	200000	USD
CY2017	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	500000	USD
CY2015	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	27747000	shares
CY2016	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	27449000	shares
CY2017	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	31427000	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27747000	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27449000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31427000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	24333000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	27433000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	31420000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24333000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27433000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31420000	shares
CY2017	bvx	Convertible Preferred Stock And Warrants Disclosure ConvertiblePreferredStockAndWarrantsDisclosure	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONVERTIBLE PREFFERED STOCK AND WARRANTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2013 Financing</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">December 13, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a securities purchase agreement with certain investors for the private placement, for aggregate gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, of </font><font style="font-family:inherit;font-size:10pt;">3,500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company’s newly-designated </font><font style="font-family:inherit;font-size:10pt;">Series A 6% Convertible Preferred Stock</font><font style="font-family:inherit;font-size:10pt;"> (the “Series A Preferred Stock” – see Note 6) and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">5,250,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.387</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the placement of the Series A Preferred Stock and warrants, we also issued warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">525,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, with the same terms as the investor warrants, to the placement agent.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the holders of the Series A Preferred Stock could have requested redemption on or after December 13, 2017, the preferred stock had conditions for its redemption that were not within the control of the Company. Accordingly, the carrying amount of the Series A Preferred Stock of </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">, net of the expenses allocated to the preferred stock of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, was recorded outside of stockholders’ equity, as mezzanine equity, in accordance with FASB ASC 480-10-S99. The net carrying amount of the Series A Preferred Stock was accreted to its redemption value over the </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> year period to when the holders may request redemption, using an effective interest method. For the year ended December 31, 2015, additional accretion of </font><font style="font-family:inherit;font-size:10pt;">$221,902</font><font style="font-family:inherit;font-size:10pt;"> was recognized. During 2015, the Series A Preferred Stock and certain related common warrants were exchanged for Series B Preferred Stock. As a result the net carrying amount of the Series A Preferred Stock at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reconciliation of changes in fair value</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain assets and liabilities that are measured at fair value on a recurring basis are measured in accordance with FASB ASC Topic 820-10-05, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;">. FASB ASC Topic 820-10-05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The statement requires fair value measurement be classified and disclosed in one of the following three categories:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Our derivative financial instruments that are measured at fair value on a recurring basis are all measured at fair value using Level 3 inputs. Level 3 inputs are unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a reconciliation of the changes in fair value of warrants measured at fair value using Level 3 inputs during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Placement Agent Warrants</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(698</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The warrants are valued using a trinomial lattice model. Significant assumptions used in the model at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, include the market price of our common stock, an expected dividend yield of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">, remaining life of </font><font style="font-family:inherit;font-size:10pt;">2.0 years</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2.5 years</font><font style="font-family:inherit;font-size:10pt;">, historical volatility of </font><font style="font-family:inherit;font-size:10pt;">24.359%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">82.470%</font><font style="font-family:inherit;font-size:10pt;"> and risk-free rates of return of </font><font style="font-family:inherit;font-size:10pt;">1.798%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">1.470%</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the remaining </font><font style="font-family:inherit;font-size:10pt;">40,000</font><font style="font-family:inherit;font-size:10pt;"> placement agent warrants was approximately </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$203,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div>
CY2017	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generally do not use derivative financial instruments to hedge exposures to cash-flow risks or market risks. However, certain financial instruments, such as warrants, which are indexed to our common stock, are classified as liabilities when either (a) the holder possesses rights to net-cash settlement or (b) physical or net-share settlement is not within our control. In such instances, net-cash settlement is assumed for financial accounting and reporting purposes, even if the terms of the underlying contracts do not always provide for net-cash settlement. Such financial instruments are initially recorded and continuously carried, at fair value.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Determining the fair value of these instruments involves judgment and the use of certain relevant assumptions including, but not limited to, interest rate risk, historical volatility and stock price, estimated life of the derivative, anti-dilution provisions and conversion/redemption privileges. The use of different assumptions or changes in those assumptions could have a material effect on the estimated fair value amounts.</font></div></div>
CY2017	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other</font><font style="font-family:inherit;font-size:10pt;"> (Topic 350): </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Test for Goodwill Impairment</font><font style="font-family:inherit;font-size:10pt;">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit's fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, however we have chosen not to do so. The amendment is not expected to have a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">. The new guidance clarifies the classification of certain cash receipts and cash payments in the statement of cash flows, including debt prepayment or extinguishment costs, settlement of contingent consideration arising from a business combination, insurance settlement proceeds, and distributions from certain equity method investees. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted, however we have chosen not to do so. The amendment is not expected to have a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, FASB issued ASU No. 2016-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Compensation-Stock Compensation - (Topic 718)</font><font style="font-family:inherit;font-size:10pt;"> Improvements to employee share-based payments accounting as part of simplicity initiatives. This update involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. For us, the amendments in this Update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The amendment has not made a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09 (ASC 606), </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No. 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for us on January 1, 2018. Early adoption is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We performed an analysis and concluded that the amendment will not have a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2014-09 (ASC 606), </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> will become effective for us beginning with the first quarter of 2018, and we plan to adopt the new accounting standard using the modified retrospective transition approach. The modified retrospective transition approach will recognize any changes from the beginning of the year of initial application through retained earnings with no restatement of comparative periods. We will record revenue under ASC 606 at a single point in time, when control is transferred to the customer, which is consistent with past practice. We will continue to apply our current business processes, policies, systems and controls to support recognition and disclosure under the new standard. Based on the results of the evaluation, we have determined that the adoption of the new standard will have a material impact on our consolidated financial statements. Application of the transition requirements of the new standard will not have a material impact on opening retained earnings.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions we are required to make.</font></div></div>

Files In Submission

Name	View Source	Status
0000719135-18-000015-index-headers.html	Edgar Link	pending
0000719135-18-000015-index.html	Edgar Link	pending
0000719135-18-000015.txt	Edgar Link	pending
0000719135-18-000015-xbrl.zip	Edgar Link	pending
a2017bvx10-k.htm	Edgar Link	pending
a2017bvx10-kexhibit1016.htm	Edgar Link	pending
a2017bvx10-kexhibit1017.htm	Edgar Link	pending
a2017bvx10-kexhibit211.htm	Edgar Link	pending
a2017bvx10-kexhibit231.htm	Edgar Link	pending
a2017bvx10-kexhibit311.htm	Edgar Link	pending
a2017bvx10-kexhibit312.htm	Edgar Link	pending
a2017bvx10-kexhibit321.htm	Edgar Link	pending
a2017bvx10-kexhibit322.htm	Edgar Link	pending
a2017bvxlogo.jpg	Edgar Link	pending
a2017bvxstockperformance.jpg	Edgar Link	pending
bvx-20171231.xml	Edgar Link	completed
bvx-20171231.xsd	Edgar Link	pending
bvx-20171231_cal.xml	Edgar Link	unprocessable
bvx-20171231_def.xml	Edgar Link	unprocessable
bvx-20171231_lab.xml	Edgar Link	unprocessable
bvx-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2016 Q4 Form 10-K Financial Statement

#000071913518000015 Filed on March 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2016 Q4 Form 10-K Financial Statement

#000071913518000015 Filed on March 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx